The Edaravone (MCI-186) ALS 19 Study Group¹ reported on the safety and efficacy of edaravone in a phase 3 study of patients with early-stage amyotrophic lateral sclerosis. The primary endpoint was change in the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) scores from baseline to 24 weeks after randomisation. Before randomisation, patients entered a 12-week observation period, and those patients with a decrease in ALSFRS-R score of 1–4 points were randomly assigned to receive edaravone or placebo.

中文翻译：

---

依达拉奉治疗早期ALS

依达拉奉（MCI-186）ALS 19研究组¹在早期肌萎缩性侧索硬化症患者的3期研究中报告了依达拉奉的安全性和有效性。主要终点是修订后的肌萎缩性侧索硬化功能评分量表（ALSFRS-R）评分从基线到随机分组后24周的变化。在随机分组之前，患者进入为期12周的观察期，并且ALSFRS-R得分降低1-4分的患者被随机分配接受依达拉奉或安慰剂治疗。